• Swiss Nordic Bio 2022

    Back to physical & on site in Zürich - registration NOW possible

  • Keynote speaker 2021

    Mikael Dolsten M.D., Ph.d. Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer

  • 1-on-1 partnering meetings

    Book 1-on-1 meetings online with your potential partners - over 400 meetings in one + one day

  • High-level networking

    >75 investors and >10 scouting/business development executives from pharma/diagnostic companies are expected at an exclusive event with max. 200 participants in total

  • Connecting Healthcare Innovations, Investors and Industry

    This high-level Swiss-Nordic exclusive investement and partnering meeting gathers Europe´s leading executives from biotech, pharmaceutical, medtech and diagnostic companies as well as investors from Switzerland and the Nordic countries

  • Pitch your innovation

    Pitch your product & business model to leading investors & pharma and get your innovation to the direct attention of real decision makers

SWISS NORDIC BIO 2022 BACK TO PHYSICAL

Swiss Nordic Bio is a high-level partnering and investor conference aimed at connecting healthcare innovations, investor and industry.
  • The conference is the number one platform that gathers life science professionals from Switzerland and the Nordic countries under one roof. 
  • The conference is organised by the Nordic countries in cooperation with Swiss partners.

The Swiss Nordic Bio Team aims to host the conference again in physical format on 25 January 2022 in Zürich.

NORDIC LIFE SCIENCE NEWS
The leading Nordic life science news service

SWISS NORDIC BIO AT A GLANCE

200

participants

75

and more investors

400

one-to-one meetings

40

and more company pitches

CO-HOSTS

PARTNERS

REGISTRATION
LOGIN

IMPORTANT DEADLINES

21 Jan 2022
End of registration

TBC
Booking of 1-to-1 meetings

25 Jan 2022
Event date

Simple Social Media Stream: There is no feed to show or there is a connectivity problem!

PREVIOUS PARTICIPANTS

Apus Capital
ArchiMed
BB Biotech
Credit Suisse
Eiffel Investment Group
Veraison Capital AG 
Johnson and Johnson Innovation
Novartis Venture Fund
Occident Group
Redalpine Venture Partners
F.Hoffmann-La Roche Ltd
Capital Rewards Partners
Creathor Venture
Management GmbH
Endeavour Vision SA
Merck Ventures BV
Novo A/S (Ventures)
Debiopharm International SA
Lipum AB
Bay City Capital
HBM Partners Ltd.
Industrifonden
MTIP MedTech Innovation Partners AG
PM Equity Partner
Signature Seven Partners
Wille Finance AG
XOventure GmbH
Sunstone Capital
Dottikon Exclusive Synthesis AG

MAIN SPONSOR

IN COOPERATION WITH

MEDIA PARTNERS